Daniel Atar
Boston Children's Hospital
11 Papers
Daniel Atar is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Antigen. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome.
Ann-Christin Pecher,Reinhild Klein,Rebekka Schairer,Katrin Lutz,Daniel Atar,Christian Seitz,A. Stanger,C. Braun,Marina Schmidt,Antje Bornemann,Christoph Faul,Wolfgang Bethge,J. Henes,Claudia Lengerke +13 more
TL;DR: In this paper , a patient with antisynthetase syndrome with progressive myositis and interstitial lung disease refractory to available therapies (including rituximab and azathioprine), who was treated with CD19-targeting CAR T cells in June 2022 at University Hospital Tübingen, Germany, with the last follow-up in February 2023.
95
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Christian Seitz,Sarah Schroeder,Philipp Knopf,Ann-Christin Krahl,Jana Hau,Sabine Schleicher,Manuela Martella,Leticia Quintanilla-Martinez,Manfred Kneilling,Bernd J. Pichler,Bernd J. Pichler,Peter Lang,Daniel Atar,Karin Schilbach,Rupert Handgretinger,Rupert Handgretinger,Patrick Schlegel,Patrick Schlegel +17 more
TL;DR: The data strongly support previous findings of GD2 as a BCSC-associated antigen and should be considered a promising novel approach for GD2-positive breast cancer, especially to eliminate disseminated tumor cells and prevent metastasis formation.
82
Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
Guillermo Ureña-Bailén,J. Dobrowolski,Yujuan Hou,Alicia Dirlam,A. Roig-Merino,Sabine Schleicher,Daniel Atar,Christian Seitz,Judith Feucht,Justin S. Antony,Tahereh Mohammadian Gol,Rupert Handgretinger,Markus Mezger +12 more
TL;DR: Results indicate that the CD19-CAR and CD276-CAR-NK−92 cell lines’ cytotoxic performance is suitable for leukemia killing, making them promising off-the-shelf therapeutic candidates.
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Daniel Nixdorf,M. Sponheimer,Darlene Berghammer,Fabian Engert,Nóra Philipp,Marzieh Kazerani,Tobias Straub,Lisa Rohrbacher,Lucas E. Wange,Sandra Dapa,Daniel Atar,Christian Seitz,Katharina Brandstetter,Andrea Linder,M. von Bergwelt,K. Leonhardt,Joerg Mittelstaet,Andrew Kaiser,Veit Bücklein,Marion Subklewe +19 more
TL;DR: In this article , a Fab-based adapter CAR (AdCAR) T-cell platform with flexibility of targeting and control of AdCAR activation was established for treating acute myeloid leukemia (AML) patients.
29
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
TL;DR: The clinical evaluation of AdCAR T cells in lymphoma as a new concept ofCAR T cell immunotherapy may overcome treatment failure due to antigen immune escape in monotargeted conventional CAR T cell therapies.